Okpebholo Inspect Roads Across Benin Metropolis Says Massive Repair To Commence
NiveshIQ
NSE: METROPOLIS · Healthcare
Metropolis Healthcare Ltd.
₹559.90▲ ₹14.25 (+2.61%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on METROPOLIS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Metropolis Healthcare Ltd.
Metropolis Healthcare Limited operates a nationwide pathology and diagnostic network, offering routine and specialised tests, advanced genetic and molecular diagnostics, and radiology services such as X‑ray, sonography and ECG. The company’s revenue of ₹1,710 cr in FY 2025 was driven by a 12% YoY increase in core pathology volumes and a 15% rise in corporate wellness contracts. Recent initiatives include expanding home‑collection services and launching a digital platform for patient self‑service, which are expected to boost first‑time test uptake by 8% annually. Metropolis maintains a strong competitive position with a 35% market share in India’s diagnostic sector, supported by strategic partnerships with major hospital chains and a robust supply‑chain network. The firm’s net income of ₹20
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,208 Cr +5.18% | ₹1,331 Cr +10.23% | ₹1,646 Cr +23.64% |
| EBITDA Margin | 23.40% | 22.76% | 24.36% |
| Net Profit | ₹127.82 Cr -10.54% | ₹144.97 Cr +13.42% | ₹190.02 Cr +31.08% |
| EPS | ₹24.95 | ₹28.29 | ₹9.19 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Metropolis Healthcare Ltd is Rated Hold
Metropolis Healthcare Ltd is Rated Hold
🔒
+ 3 more stories about Metropolis Healthcare Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹450 Cr, PAT ₹57 Cr, EPS ₹2.73, EBITDA margin 24.7%. Growth context: revenue YoY +16.6%, PAT YoY +25.8%, revenue QoQ +6.0%, PAT QoQ +11.3%. Street verdict: inline, revenue surprise +0.9%, PAT surprise +3.5%.
Recent corporate activity highlights geographic expansion and international growth and R&D investments and technology in...
FY26 (last completed FY): revenue ₹1, 646 Cr, PAT ₹190 Cr, EBITDA margin 24.4%, EPS ₹9.19. Year-on-year: revenue YoY +23...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for METROPOLIS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track METROPOLIS alongside your other holdings
Unlock full METROPOLIS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Metropolis Healthcare Ltd.?
NiveshIQ detects active intelligence signals for Metropolis Healthcare Ltd. (METROPOLIS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Metropolis Healthcare Ltd.?
Metropolis Healthcare Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,138,229.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.